After Years Of Waiting, FDA Classifies Anthrax Detection Devices As Class II
A new guidance document and final rule from US FDA on Bacillus bacteria detection devices, which are used to diagnose anthrax, place the pre-amendment devices in class II.
You may also be interested in...
A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.
Medtronic gets February panel date for its DIAM spine device, which would be the firm's second interspinous spacer on the market; FDA moves risk classifications forward for five device types; and the agency continues its scrutiny of direct-to-consumer genetic tests.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.